Cover Image
市場調查報告書

過敏性氣喘:開發平台分析

Allergic Asthma - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 255948
出版日期 內容資訊 英文 181 Pages
訂單完成後即時交付
價格
Back to Top
過敏性氣喘:開發平台分析 Allergic Asthma - Pipeline Review, H2 2016
出版日期: 2016年08月10日 內容資訊: 英文 181 Pages
簡介

過敏性氣喘是最常見的氣喘。過敏是人體免疫系統為了防禦細菌、病毒侵害身體的一般作用,具有過敏症狀的人,部分免疫系統過於敏感。甚至連無害物質(貓的皮屑或花粉)也被人體(鼻、肺、皮膚接觸)視為入侵攻擊的有害物質。過敏性氣喘就是氣管對過敏原非常敏感。如果過敏原進入氣管,免疫系統就會引起過度反應,造成氣管周圍的肌肉僵硬(支氣管痙攣),氣管上也會因發炎包覆厚厚黏液。氣喘的治療方法有口服抗發炎藥及氣管擴張藥,或是利用吸入器來服用氣喘治療藥等許多種。

本報告提供全球各國治療過敏性氣喘所用的開發中產品開發情形相關分析,提供您開發中產品的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等調查資訊。

簡介

  • 分析範圍

過敏性氣喘概要

治療藥的開發

  • 過敏性氣喘開發中產品:概要
  • 過敏性氣喘開發中產品:比較分析

各企業開發中的過敏性氣喘治療藥

大學/研究機關研究中的過敏性氣喘治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

過敏性氣喘治療藥:開發中的產品的一覽(各企業)

按過敏性氣喘治療藥:研究中的產品的一覽(大學/研究機關)

過敏性氣喘開發治療藥的企業

  • ALK-Abello A/S
  • Allergopharma GmbH & Co. KG
  • Amgen Inc.
  • Aquinox Pharmaceuticals Inc.
  • ASIT biotech s.a.
  • Aslan Pharmaceuticals Pte. Ltd.
  • Axikin Pharmaceuticals, Inc.
  • Baxalta Incorporated
  • Chiesi Farmaceutici SpA
  • Circassia Pharmaceuticals Plc
  • CSL Limited
  • Fountain Biopharma Inc.
  • GlaxoSmithKline Plc
  • Hydra Biosciences, Inc.
  • Infinity Pharmaceuticals, Inc.
  • Kineta, Inc.
  • Mabtech Limited
  • Marinomed Biotechnologie GmbH
  • Mycenax Biotech Inc.
  • NeoPharm Co., Ltd.
  • Oxagen Limited
  • Panacea Biotec Limited
  • Peptinnovate Limited
  • Pharmaxis Limited
  • Protectimmun GmbH
  • Stallergenes SAS
  • sterna biologicals Gmbh & Co KG
  • Swecure AB
  • The International Biotechnology Center (IBC) Generium
  • Verona Pharma Plc

過敏性氣喘:治療藥的評估

  • 單劑治療藥的情況
  • 標的別
  • 各行動機制
  • 各投藥法
  • 各分子類型
  • 各治療分類

藥物簡介

  • AcTMP-1
    • 產品概要
    • 功能機制
    • 研究開發(R&D)的發展情形
  • AMG-282
  • AQX-1125
  • Arabinogalactan
  • ASLAN-004
  • ASM-8
  • AXP-1275
  • beta-escin
  • CHF-6001
  • CSL-311
  • dalazatide
  • Drug to Inhibit PI3 Kinase Delta for Asthma
  • duvelisib
  • EP-67
  • FB-825
  • GNR-044
  • GSK-2245035
  • hdm-ASIT
  • HX-100
  • Lactococcus lactis G121
  • Leukothera
  • OC-000459
  • OC-2417
  • omalizumab biosimilar
  • omalizumab biosimilar
  • omalizumab biosimilar
  • omalizumab biosimilar
  • omalizumab biosimilar
  • omalizumab biosimilar
  • OND-86
  • pemirolast potassium
  • pentosan polysulfate sodium
  • PIN-201601
  • RPL-554
  • S-1226
  • SB-010
  • SG-100
  • SM-301
  • Small Molecule for Allergic Asthma
  • Small Molecules for Allergic Asthma
  • Small Molecules to Inhibit CaMKII for Allergic Asthma
  • standardized grass pollen [timothy (Phleum pratense)] allergen extract
  • standardized mite (Dermatophagoides farinae + Dermatophagoides pteronyssinus) allergen extract
  • standardized mite (Dermatophagoides pteronyssinus + Dermatophagoides farinae) allergen extract
  • SWE-01
  • tezepelumab
  • Vaccine for Allergic Rhinitis and Allergic Asthma
  • Vaccine for Grass-Induced Rhinoconjunctivitis and Asthma

過敏性氣喘治療藥:最新的藥物簡介

過敏性氣喘治療藥:開發暫停的產品

過敏性氣喘治療藥:開發中止的產品

過敏性氣喘相關產品的開發的里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8350IDB

Summary

Global Markets Direct's, 'Allergic Asthma - Pipeline Review, H2 2016', provides an overview of the Allergic Asthma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Allergic Asthma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Allergic Asthma and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Allergic Asthma
  • The report reviews pipeline therapeutics for Allergic Asthma by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Allergic Asthma therapeutics and enlists all their major and minor projects
  • The report assesses Allergic Asthma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Allergic Asthma

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Allergic Asthma
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Allergic Asthma pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Allergic Asthma Overview
  • Therapeutics Development
    • Pipeline Products for Allergic Asthma - Overview
    • Pipeline Products for Allergic Asthma - Comparative Analysis
  • Allergic Asthma - Therapeutics under Development by Companies
  • Allergic Asthma - Therapeutics under Investigation by Universities/Institutes
  • Allergic Asthma - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Allergic Asthma - Products under Development by Companies
  • Allergic Asthma - Products under Investigation by Universities/Institutes
  • Allergic Asthma - Companies Involved in Therapeutics Development
    • ALK-Abello A/S
    • Allergopharma GmbH & Co. KG
    • Amgen Inc.
    • Aquinox Pharmaceuticals Inc.
    • ASIT biotech s.a.
    • Aslan Pharmaceuticals Pte. Ltd.
    • Chiesi Farmaceutici SpA
    • Circassia Pharmaceuticals Plc
    • CSL Limited
    • F. Hoffmann-La Roche Ltd.
    • Fountain Biopharma Inc.
    • Genentech, Inc.
    • GlaxoSmithKline Plc
    • Hydra Biosciences, Inc.
    • Infinity Pharmaceuticals, Inc.
    • KPI Therapeutics, Inc.
    • Mabtech Limited
    • Marinomed Biotechnologie GmbH
    • Mycenax Biotech Inc.
    • NeoPharm Co., Ltd.
    • Oxagen Limited
    • Panacea Biotec Limited
    • Paradigm Biopharmaceuticals Limited
    • Pharmaxis Limited
    • Protectimmun GmbH
    • Shire Plc
    • Stallergenes Greer plc
    • sterna biologicals Gmbh & Co KG
    • Swecure AB
    • Synermore Biologics Co Ltd
    • The International Biotechnology Center (IBC) Generium
    • Verona Pharma Plc
    • Xencor, Inc.
  • Allergic Asthma - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AcTMP-1 - Drug Profile
    • Allergen for Allergic Asthma and Allergic Rhinitis - Drug Profile
    • AQX-1125 - Drug Profile
    • Arabinogalactan - Drug Profile
    • ASLAN-004 - Drug Profile
    • ASM-8 - Drug Profile
    • beta-escin - Drug Profile
    • CHF-6001 - Drug Profile
    • CSL-311 - Drug Profile
    • dalazatide - Drug Profile
    • Drug to Inhibit PI3 Kinase Delta for Asthma - Drug Profile
    • duvelisib - Drug Profile
    • EP-67 - Drug Profile
    • Epsi-Gam - Drug Profile
    • FB-825 - Drug Profile
    • GNR-044 - Drug Profile
    • GSK-2245035 - Drug Profile
    • hdm-ASIT - Drug Profile
    • HX-100 - Drug Profile
    • Lactococcus lactis G121 - Drug Profile
    • Leukothera - Drug Profile
    • OC-000459 - Drug Profile
    • OC-2417 - Drug Profile
    • omalizumab biosimilar - Drug Profile
    • omalizumab biosimilar - Drug Profile
    • omalizumab biosimilar - Drug Profile
    • omalizumab biosimilar - Drug Profile
    • omalizumab biosimilar - Drug Profile
    • OND-86 - Drug Profile
    • pemirolast potassium - Drug Profile
    • pentosan polysulfate sodium - Drug Profile
    • RG-6149 - Drug Profile
    • RG-7990 - Drug Profile
    • RPL-554 - Drug Profile
    • SB-010 - Drug Profile
    • SG-100 - Drug Profile
    • SM-301 - Drug Profile
    • Small Molecule for Allergic Asthma - Drug Profile
    • Small Molecules for Allergic Asthma - Drug Profile
    • Small Molecules to Inhibit 5-Lipoxygenase for Allergic Asthma - Drug Profile
    • Small Molecules to Inhibit CaMKII for Allergic Asthma - Drug Profile
    • standardized grass pollen [timothy (Phleum pratense)] allergen extract - Drug Profile
    • standardized mite (Dermatophagoides farinae + Dermatophagoides pteronyssinus) allergen extract - Drug Profile
    • standardized mite (Dermatophagoides pteronyssinus + Dermatophagoides farinae) allergen vaccine - Drug Profile
    • SWE-01 - Drug Profile
    • Synthetic Peptides for Allergic Asthma and Rheumatoid Arthritis - Drug Profile
    • tezepelumab - Drug Profile
    • Vaccine for Allergic Asthma - Drug Profile
    • Vaccine for Grass-Induced Rhinoconjunctivitis and Asthma - Drug Profile
    • XmAb-7195 - Drug Profile
  • Allergic Asthma - Dormant Projects
  • Allergic Asthma - Discontinued Products
  • Allergic Asthma - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Allergic Asthma, H2 2016
  • Number of Products under Development for Allergic Asthma - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Allergic Asthma - Pipeline by ALK-Abello A/S, H2 2016
  • Allergic Asthma - Pipeline by Allergopharma GmbH & Co. KG, H2 2016
  • Allergic Asthma - Pipeline by Amgen Inc., H2 2016
  • Allergic Asthma - Pipeline by Aquinox Pharmaceuticals Inc., H2 2016
  • Allergic Asthma - Pipeline by ASIT biotech s.a., H2 2016
  • Allergic Asthma - Pipeline by Aslan Pharmaceuticals Pte. Ltd., H2 2016
  • Allergic Asthma - Pipeline by Chiesi Farmaceutici SpA, H2 2016
  • Allergic Asthma - Pipeline by Circassia Pharmaceuticals Plc, H2 2016
  • Allergic Asthma - Pipeline by CSL Limited, H2 2016
  • Allergic Asthma - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
  • Allergic Asthma - Pipeline by Fountain Biopharma Inc., H2 2016
  • Allergic Asthma - Pipeline by Genentech, Inc., H2 2016
  • Allergic Asthma - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Allergic Asthma - Pipeline by Hydra Biosciences, Inc., H2 2016
  • Allergic Asthma - Pipeline by Infinity Pharmaceuticals, Inc., H2 2016
  • Allergic Asthma - Pipeline by KPI Therapeutics, Inc., H2 2016
  • Allergic Asthma - Pipeline by Mabtech Limited, H2 2016
  • Allergic Asthma - Pipeline by Marinomed Biotechnologie GmbH, H2 2016
  • Allergic Asthma - Pipeline by Mycenax Biotech Inc., H2 2016
  • Allergic Asthma - Pipeline by NeoPharm Co., Ltd., H2 2016
  • Allergic Asthma - Pipeline by Oxagen Limited, H2 2016
  • Allergic Asthma - Pipeline by Panacea Biotec Limited, H2 2016
  • Allergic Asthma - Pipeline by Paradigm Biopharmaceuticals Limited, H2 2016
  • Allergic Asthma - Pipeline by Pharmaxis Limited, H2 2016
  • Allergic Asthma - Pipeline by Protectimmun GmbH, H2 2016
  • Allergic Asthma - Pipeline by Shire Plc, H2 2016
  • Allergic Asthma - Pipeline by Stallergenes Greer plc, H2 2016
  • Allergic Asthma - Pipeline by sterna biologicals Gmbh & Co KG, H2 2016
  • Allergic Asthma - Pipeline by Swecure AB, H2 2016
  • Allergic Asthma - Pipeline by Synermore Biologics Co Ltd, H2 2016
  • Allergic Asthma - Pipeline by The International Biotechnology Center (IBC) Generium, H2 2016
  • Allergic Asthma - Pipeline by Verona Pharma Plc, H2 2016
  • Allergic Asthma - Pipeline by Xencor, Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Allergic Asthma - Dormant Projects, H2 2016
  • Allergic Asthma - Dormant Projects (Contd..1), H2 2016
  • Allergic Asthma - Dormant Projects (Contd..2), H2 2016
  • Allergic Asthma - Dormant Projects (Contd..3), H2 2016
  • Allergic Asthma - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Allergic Asthma, H2 2016
  • Number of Products under Development for Allergic Asthma - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Top 10 Routes of Administration, H2 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top